Episode 8. Management of Newly Diagnosed CLL
Blood Cancer Talks
00:00
The Trial of Brute-Neplax in Other Supervision and EJM
The number of patients have become too small in those subgroups and they were not powered for comparisons. So it's difficult to make conclusions out of it, but just to answer your point, some of these trials are being done with which are MRD directed treatment. Now let's talk about your trial of Brute-Neplax combination in other supervision and EJM. Can you give us an overview of the trial design and what were the key takeaway messages from that study?
Transcript
Play full episode
